secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001070081-24-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC reports prelim 2023 revenue $946M (+35% YoY); guides 2024 rev $600-850M
---------------------------------------------------------------------------

- Unaudited 2023 total revenue $946M (+35% YoY); net product revenue $661M (+23% YoY).
- DMD franchise: Translarna $355M, Emflaza $255M; Evrysdi royalty/collab revenue $278M.
- 2024 revenue guidance $600-850M (decline); GAAP R&D+SG&A $740-835M; non-GAAP $660-755M.
- Sepiapterin MAA in EU Q1, NDA in US by Q3; PTC518 HD interim data Q2.
- CHMP opinion on Translarna re-examination late Jan 2024; $1B Royalty Pharma deal closed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/0001070081-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/tmb-20240108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer